Human ADME Study of [14C]-AZD1390
ConditionAdvanced Solid Malignancies
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-99
SponsorAstraZeneca
About this trial
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of \[14C\]-AZD1390.
Eligibility criteria
Qualifiers
Participants with Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, no active anticancer treatment,
ECOG performance status of 0 or 1 with no deterioration over the 2 weeks,
Predicted life expectancy ≥ 12 weeks,
Adequate organ and marrow function,
Disqualifiers
History or presence of myopathy or raised CK > 5 × ULN at screening,
History of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment,
History or presence of clinically significant hepatic disease,
History of epileptic disorder or any seizure history unrelated to tumour,
Trial design
Treatments tested in this trial
- AZD1390
Treatment groups
8 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov